188 Company balance sheet UK GAAP at 31st December 2010 2010 2009 Notes m m Fixed assets investments D 19,659 19,632 Debtors E 720 736 Cash at bank 10 9 Current assets 730 745 Creditors: amounts due within one year F 6,230 3,068 Net current liabilities 5,500 2,323 Net assets 14,159 17,309 Capital and reserves Called up share capital G 1,418 1,416 Share premium account G 1,428 1,368 Other reserves H 1,282 1,255 Profit and loss account H 10,031 13,270 Equity shareholders funds 14,159 17,309 Approved by the Board on 1st March 2011.
Sir Christopher Gent Chairman GlaxoSmithKline plc Registered number: 3888792 GSK Annual Report 2010 Financial statements P102P191 Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 189 Notes to the company balance sheet UK GAAP Expenditure A Presentation of the financial statements Expenditure is recognised in respect of goods and services received Description of business when supplied in accordance with contractual terms.
Provision is GlaxoSmithKline plc is the parent company of GSK, a major global made when an obligation exists for a future liability in respect of healthcare group which is engaged in the creation and discovery, a past event and where the amount of the obligation can be development, manufacture and marketing of pharmaceutical reliably estimated.
products, including vaccines, over-the-counter OTC medicines and health-related consumer products.
Investments in subsidiary companies Investments in subsidiary companies are held at cost less any Preparation of financial statements provision for impairment.
The financial statements, which are prepared on a going concern basis, are drawn up in accordance with UK generally accepted Impairment of investments accounting principles UK GAAP and with UK accounting The carrying value of investments are reviewed for impairment presentation as at 31st December 2010, with comparative gures when there is an indication that the investment might be impaired.
Where appropriate, comparative Any provision resulting from an impairment review is charged to gures are reclassied to ensure a consistent presentation with the income statement in the year concerned.
Share based payments As permitted by s. 408 of the Companies Act 2006, the profit and The issuance by the company to its subsidiaries of a grant over loss account of the company is not presented in this Annual Report.
the companys options, represents additional capital contributions by the company in its subsidiaries.
An additional investment in Accounting convention and standards subsidiaries results in a corresponding increase in shareholders The balance sheet has been prepared using the historical cost equity.
The additional capital contribution is based on the fair convention and complies with applicable UK accounting standards.
value of the grant issued, allocated over the underlying grants Accounting principles and policies vesting period.
The preparation of the balance sheet in conformity with generally Taxation accepted accounting principles requires management to make Current tax is provided at the amounts expected to be paid estimates and assumptions that affect the reported amounts applying tax rates that have been enacted or substantially enacted of assets and liabilities and disclosure of contingent assets and by the balance sheet date.
liabilities at the date of the balance sheet.
Actual amounts could differ from those estimates.
The company accounts for taxation which is deferred or accelerated by reason of timing differences which have originated but not The balance sheet has been prepared in accordance with the reversed by the balance sheet date.
Deferred tax assets are only companys accounting policies approved by the Board and recognised to the extent that they are considered recoverable described in Note B. against future taxable profits.
B Accounting policies Deferred tax is measured at the average tax rates that are expected to apply in the periods in which the timing differences Foreign currency transactions are expected to reverse.
Deferred tax liabilities and assets are Foreign currency transactions are recorded at the exchange rate not discounted.
ruling on the date of transaction, or at the forward rate if hedged by a forward exchange contract.
Foreign currency assets and Financial guarantees liabilities are translated at rates of exchange ruling at the balance Liabilities relating to guarantees issued by the company on behalf sheet date, or at the forward rate.
of its subsidiaries are initially recognised at fair value and amortised over the life of the guarantee.
Dividends paid and received Dividends paid and received are included in the accounts in the C Operating profit period in which the related dividends are actually paid or received.
A fee of 11,140 2009 11,140 relating to the audit of the company has been charged in operating profit.
GSK Annual Report 2010 190 Notes to the company balance sheet UK GAAP D Fixed assets 2010 2009 m m Shares in GlaxoSmithKline Services Unlimited 613 613 Shares in GlaxoSmithKline Holdings One Limited 18 18 Shares in GlaxoSmithKline Holdings Limited 17,888 17,888 Shares in GlaxoSmithKline Mercury Limited 33 33 18,552 18,552 Capital contribution relating to share based payments 1,107 1,080 19,659 19,632 E Debtors 2010 2009 m m Amounts due within one year: UK Corporation tax recoverable 223 228 Amounts owed by Group undertakings 112 116 335 344 Amounts due after more than one year: Amounts owed by Group undertakings 385 392 720 736 F Creditors 2010 2009 m m Amounts due within one year: Bank overdraft 9 8 Amounts owed to Group undertakings 5,774 2,606 Other creditors 447 454 6,230 3,068 The company has guaranteed debt issued by one of its subsidiary companies for which it receives an annual fee from the subsidiary.
In aggregate, the company has outstanding guarantees over $10 billion of debt instruments.
The amount due from the subsidiary companies in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within debtors see Note E. GSK Annual Report 2010 Financial statements P102P191 Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 191 Notes to the company balance sheet UK GAAP G Share capital and share premium account Share Ordinary Shares of 25p each premium Number m m Share capital authorised At 31st December 2009 10,000,000,000 2,500 At 31st December 2010 10,000,000,000 2,500 Share capital issued and fully paid At 1st January 2009 5,661,316,237 1,415 1,326 Issued under share option schemes 3,812,482 1 42 At 31st December 2009 5,665,128,719 1,416 1,368 Issued under share option schemes 5,329,458 2 60 At 31st December 2010 5,670,458,177 1,418 1,428 31st December 31st December 2010 2009 Number 000 of shares issuable under outstanding options 207,132 213,110 Number 000 of unissued shares not under option 4,122,410 4,121,761 At 31st December 2010, of the issued share capital, 105,472,070 shares were held in the ESOP Trust, 474,194,158 shares were held as Treasury shares and 5,090,791,949 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trust are disclosed in Note 42, Employee share schemes.
The company did not purchase any of its own shares in 2010.
On 3rd February 2011, GSK announced that it would commence a new long-term share buy-back programme and expected to repurchase 1-2 billion of shares, depending on market conditions, in 2011.
The exact amount and timing of purchases and whether the shares will be held as Treasury shares or be cancelled will be determined by the company and is dependent on market conditions and other factors.
No shares were purchased in the period 1st January 2011 to 3rd February 2011.
In the period 4th February 2011 to 24th February 2011 10.4 million shares were purchased at a cost of 123.4 million.
H Reserves Other profit and reserves loss account Total m m m At 1st January 2009 1,216 11,273 12,489 Profit attributable to shareholders 5,000 5,000 Dividends to shareholders 3,003 3,003 Capital contribution relating to share based payments 39 39 At 31st December 2009 1,255 13,270 14,525 Loss attributable to shareholders 34 34 Dividends to shareholders 3,205 3,205 Capital contribution relating to share based payments 27 27 At 31st December 2010 1,282 10,031 11,313 The loss of GlaxoSmithKline plc for the year was 34 million 2009 profit of 5,000 million, which after dividends of 3,205 million 2009 3,003 million, gave a retained loss of 3,239 million 2009 profit of 1,997 million.
The profit and loss account reserve at 31st December 2010 stood at 10,031 million 2009 13,270 million, of which 4,096 million is unrealised 2009 4,096 million.
I Post balance sheet event On 3rd February 2011, the company initiated a new long-term share buy-back programme, and the intention is to repurchase 1-2 billion of shares in 2011, depending on market conditions.
